IndraLab
Statements
Imipramine inhibits KCNH1. 25 / 27
1
1
|
25
reach
"We then used electrophysiology and site-directed mutagenesis, guided by molecular dynamics (MD) simulations, to further examine the molecular mechanism of EAG1 current inhibition by imipramine.We found that deletion of the PAS domain substantially decreased EAG1 current inhibition by imipramine, suggesting that the effect of imipramine is, at least in part, mediated via binding to the PAS domain."
reach
"Consistent with this, substitutions of D39 and R84 residues with glycine substantially decreased EAG current inhibition by imipramine.The residual inhibition of EAG1 channels lacking the PAS domain, combined with the previously reported inhibition of EAG1 channels by imipramine via an open-pore block (27), indicates that imipramine inhibits EAG1 currents by a dual mechanism: by binding to the PAS domain and by blocking the conduction pore."
reach
"These results strongly suggested that Y71 functions as a “gate-keeper” residue, restricting access of imipramine to the PAS domain cavity.To further investigate if the charge at position 71 may have an effect on EAG1 current inhibition by imipramine, Y71 was substituted for either glutamate or arginine."
reach
"We hope that the molecular mechanism of imipramine inhibition uncovered in our study will facilitate the development of EAG1 channel-specific small molecule inhibitors that bind to their intracellular PAS domains and can be used for the treatment of cancer and neurological disorders associated with defects in EAG1 channel function.The IC value for imipramine inhibition of WT EAG1 channels determined with TEVC (∼60 μM) was higher than the IC determined for EAG1 currents recorded from HEK293 in the whole-cell configuration (∼2 μM) (27)."